Cognition Therapeutics Shares Jump 33.5% After FDA Backs Phase 3 Alzheimer’s Trial

Introduction to Cognition Therapeutics Inc.

Cognition Therapeutics Inc. (ticker: CGTX) is a clinical-stage biopharmaceutical company listed on the NAS exchange. Headquartered in Purchase, New York, the firm specializes in small-molecule therapeutics designed to address age-related degenerative disorders of the central nervous system. Its lead candidate, zervimesine (also known as CT1812), aims to slow the progression of Alzheimer’s disease and dementia with Lewy bodies by targeting cellular functions critical for neuronal health.

Corporate Structure and Experience

Founded in 2007, Cognition Therapeutics employs between 11 and 50 professionals with expertise in neuroscience, drug development, and clinical research. The team’s focus areas include Alzheimer’s disease, dementia with Lewy bodies (DLB), and dry age-related macular degeneration. The company’s research platform centers on oligomer antagonists that displace toxic protein aggregates and preserve sigma-2 receptor function.

Alzheimer's research by Brett Jordan

Recent Developments and News

• On July 9, 2025, the U.S. Food and Drug Administration completed its end-of-Phase 2 meeting for zervimesine in Alzheimer’s disease. The FDA confirmed that the proposed Phase 3 program design may support a New Drug Application (NDA).
• On August 7, 2025, Cognition Therapeutics filed its quarterly report (Form 10-Q) for the period ended June 30, 2025, and a current report (Form 8-K) disclosing key corporate updates.
• Business highlights for the second quarter ended June 30, 2025, include:
  • 50 percent enrollment reached in the Phase 2 “START” study in mild cognitive impairment and early Alzheimer’s disease
  • Reduction of geographic atrophy lesion growth in the Phase 2 dry AMD program
  • Launch of an expanded access program for former DLB trial participants
  • Presentation of Phase 2 DLB results at AAIC 2025
  • Submission of a Breakthrough Therapy designation application for zervimesine in DLB
• At AAIC 2025, poster presentations detailed analyses from the Phase 2 “SHINE” study in Alzheimer’s disease, including reductions in plasma GFAP, and safety, tolerability, and efficacy outcomes from the Phase 2 “SHIMMER” study in DLB.

Financial and Strategic Analysis

As of August 14, 2025, CGTX shares traded at $1.6287, reflecting an increase of 33.50 percent on volume of 7,660,888. The August 7, 2025 Form 10-Q likely outlines research and development expenses, cash runway, and operating results. Cognition Therapeutics is advancing zervimesine toward a pivotal Phase 3 program while maintaining a pipeline that includes studies in dry AMD and dementia with Lewy bodies. The company’s oral, small-molecule approach contrasts with antibody-based therapies, potentially offering advantages in manufacturing and patient access.

Market Position and Industry Context

Cognition Therapeutics operates within the biotechnology research sector of the healthcare industry. The global market for Alzheimer’s disease and related dementias continues to attract numerous pharmaceutical and biotechnology firms pursuing disease-modifying treatments. Cognition’s focus on sigma-2 receptor modulation positions it among companies targeting intracellular pathways to clear toxic proteins. Regulatory feedback from the FDA and progress toward a Breakthrough Therapy designation underscore the importance of clinical evidence and regulatory pathways in the competitive landscape.

tl;dr

CGTX shares rose 33.50 percent to $1.6287 following the FDA’s July 9, 2025 end-of-Phase 2 feedback regarding the design of a Phase 3 program that may support an NDA for zervimesine in Alzheimer’s disease. In Q2 2025, the company reached 50 percent enrollment in its Phase 2 START study, demonstrated lesion-growth reduction in dry AMD, initiated an expanded-access program for DLB, presented DLB and Alzheimer’s biomarker data at AAIC 2025, and filed for Breakthrough Therapy designation in DLB. A Phase 3 program is planned, with the potential for NDA submission upon completion of pivotal trials.